<i>In Vivo</i> CAR T-Cell Therapy Spurs 100% ORR in Phase I

In the phase I inMMyCAR study of the in vivo chimeric antigen receptor (CAR) T-cell therapy KLN-1010, all 18 patients with multiple myeloma responded. None of the evaluable patients had minimal residual disease 1 month after treatment, suggesting that the therapy could prove clinically useful.

Publication Details

Journal
Cancer Discovery
Published
2026-06-09
DOI
https://doi.org/10.1158/2159-8290.cd-nw2026-0067
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

In Vivo CAR T-Cell Therapy Spurs 100% ORR in Phase I

Cancer Discovery
CAR-T cell therapy research
article

In Vivo CAR T-Cell Therapy Spurs 100% ORR in Phase I

article en

Abstract

In the phase I inMMyCAR study of the in vivo chimeric antigen receptor (CAR) T-cell therapy KLN-1010, all 18 patients with multiple myeloma responded. None of the evaluable patients had minimal residual disease 1 month after treatment, suggesting that the therapy could prove clinically useful.

Cancer Discovery
Good health and well-being
Openalex Percentile: Top 7%
CAR-T cell therapy research
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

<i>In Vivo</i> CAR T-Cell Therapy Spurs 100% ORR in Phase I · Cancer Discovery (2026) | TGRS Research Map | TGRS